Company news

argenx SE news in 2025

argenx SE's news releases, calls and decks from 2025, newest first.

View company

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

December 15, 2025

argenx Announces Results of Extraordinary General Meeting of Shareholders

November 18, 2025

/C O R R E C T I O N from source -- argenx Canada Inc./

November 5, 2025

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

October 30, 2025

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

October 29, 2025

argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

October 23, 2025

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

October 15, 2025

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

October 3, 2025

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

September 18, 2025

Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer

September 2, 2025

argenx to Present at Upcoming Investor Conferences

August 28, 2025

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

August 25, 2025

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

August 12, 2025

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

July 31, 2025

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

July 24, 2025

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

June 30, 2025

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

June 20, 2025

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

June 10, 2025

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

April 28, 2025

Calls in 2025

Decks in 2025